To highlight some of the recent developments in the novel field of immunometabolism and the therapeutic potential of the many regulatory components of this immunometabolic network for transplantation.
INTRODUCTION
Programming the host's immune system to induce allograft tolerance while retaining normal immune responses toward pathogens and tumors has long been the 'ultimate' goal of transplantation immunologists [1] . Recent knowledge of the immunoregulatory mechanisms involved in maternal immunity, obesity, type 2 diabetes, overnutrition-associated metabolic dysfunction, and chronic inflammation is reshaping our understanding of the interconnectivity between what once appeared to be disparate physiological systems of immunity and metabolism [2,3,4 && ]. The bidirectional coordination between these processes essential for the maintenance of homeostasis is comprised of two aspects. One deals with the effect of immune cells on organs such as adipose tissue and liver that regulate whole body metabolism, whereas the other deals with the instructive role of metabolism on immune cells in regulating their fate and function [4 && ,5 && ]. In this review, we focus on the recent findings in this still-evolving field of immunometabolism and discuss how this knowledge can help us re-evaluate our understanding of the mechanisms of immune activation and suppression, and potentially design better immunotherapeutic strategies to achieve long-term transplantation tolerance in allograft recipients.
programming, a highly coordinated activity of catabolic and anabolic pathways that produces ATP (adenosine 5 0 -triphosphate) to provide energy for cellular functions [5 && ,6 & ]. Immune cells, like most other cells, utilize substrates such as glucose, lipids, and amino acids to meet their energy demands. Under quiescent conditions, cells metabolize glucose to pyruvate that is further oxidized into acetyl CoA in the mitochondria via the TCA cycle ( Fig. 1) [7] . Similarly, fatty acids (FAs) are oxidized to acetyl CoA via fatty acid/b-oxidation (FAO) in the mitochondria [5 && ]. These processes donate electrons to the electron transport chain (ETC) to fuel mitochondrial oxidative phosphorylation (OXPHOS) to generate ATP ( Fig. 1 ).
Upon activation, however, cells undergo a metabolic shift to generate ATP primarily by converting glucose to pyruvate and then to lactate, a process known as aerobic glycolysis (Warburg effect) ( Fig. 1 ) [8, 9] . It is accompanied by the oxidation of amino acids such as glutamine that replenishes the TCA cycle ( Fig. 1) [9, 10] . This metabolic shift offers a rapid source of ATP and provides necessary biosynthetic precursors required for replication, protein and lipid synthesis vital for growth, proliferation, and differentiation [11] [12] [13] . Here, we will review some of the findings that focus on how metabolism influences the outcome of an immune response.
Metabolism in innate immune cells
In addition to promoting T-cell responses, innate immune subsets such as dendritic cells and macrophages induce antigen-specific tolerance by promoting T-cell anergy, deletion or the generation of regulatory T cells (Tregs) [2, 14] . Moreover, M2 (alternate) type macrophages attenuate renal allograft injury by facilitating wound healing and tissue remodeling [15] . Upon activation, dendritic cells undergo a metabolic shift to glycolysis, whereas M2 macrophages depend upon FAO for their development and function ( Fig. 2a) [8,5 && ,16] . Another major mechanism essential for the immune-regulatory function of innate cells is amino acid catabolism ( Fig. 2a ) [17] . Activated dendritic cells and graft endothelial cells express indoleamine 2,3-dioxygenase (IDO), an enzyme that catabolizes tryptophan via the kynurenine (kyn) pathway [18] . Along the same line, activated myeloid-derived suppressor cells (MDSCs) express two enzymes, namely arginase (Arg-1) and nitric oxide synthase (NOS) that catabolize arginine [18] . The induction of these enzymes causes a local depletion of tryptophan and arginine, increases downstream tryptophan metabolites and reactive nitrogen species (RNS) and reactive oxygen species (ROS). This results in the repression of protein translation via the blockade of phosphoinositide 3-kinase (PI3K)-the mammalian target of rapamycin (mTOR) signaling and the activation of general control nonrepressed-2 kinase (GCN2), an enzyme involved in the amino acid starvation stress response, in responding T cells leading to their proliferation arrest and apoptosis [2, 17] (Fig. 2a ).
IDO is induced upon the engagement of the costimulatory molecules CD80-CD86 on dendritic cells by cytotoxic T-lymphocyte-associated protein-4 (CTLA4) on Tregs and by interferon-g (IFN-g), whereas Arg-1 is induced by cytokines including transforming growth factor (TGF-b) and interleukin-10 (IL-10) [18] . One of the mechanisms by which CTLA4-immunoglobulin (CTLA4-Ig) suppresses the rejection of pancreatic islet allografts in vivo is in part attributed to its ability to induce IDO in dendritic cells [2, 19] . Also of interest, a small molecule, halofuginone, was found to activate the amino acid starvation response via GCN2 and inhibit Th17 differentiation while enhancing Treg development [20] . Together, these findings open an opportunity for targeting specific metabolic pathways in innate immune cells to optimize their tolerogenic-reparative potential in a transplantation setting [2, 15] .
Metabolism in T effector cells
Recently activated T cells depend upon the orphan nuclear receptor estrogen-related receptor alpha (ERRa) for the upregulation of glycolysis required for T-cell growth and proliferation ( Fig. 2b) [21] .
KEY POINTS
mTOR and AMPK are two central nutrient/energy sensors that link immunity and metabolism.
The extent to which T effector cells rely upon metabolic pathways such as glycolysis and mitochondrial oxidative phosphorylation is context dependent.
Tregs and CD8 memory T cells predominantly depend upon lipid metabolism via FAO and lipogenesis for their differentiation and function.
Incorporation of glycolytic inhibitors and FAOpromoting agents to diminish alloreactive T-cell responses and enhance Tregs may serve as a beneficial strategy during tolerance induction.
Calorie restriction can also serve as a promising alternative to mimic the effects of mTOR inhibition and can increase Treg responsiveness in tolerance induction regimens.
Moreover, glycolysis is also important for T effector (Teff) cell function, wherein it relieves the inhibition of translation of cytokine transcripts such as IL-2 and IFN-g by engaging the bifunctional glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) that otherwise binds to the 3 0 untranslated region (UTR) of the cytokine transcripts and prevents their translation ( Fig. 2b ) [22 & ]. Further, glycolysis promotes CD4 þ T-cell differentiation into various Teff populations (Th1, Th2, and Th17) and its inhibition blocks this process while promoting Tregs [23] [24] [25] .
Although glycolysis is critical in controlling T-cell responses, the model of glycolysis replacing mitochondrial OXPHOS during T-cell activation is not precisely correct, as T cells depend upon mitochondrial OXPHOS as a source of ROS required for optimal T-cell activation and expansion [10] . For instance, during graft versus host disease (GVHD) in bone marrow transplantation, in which the antigen is ubiquitously present, chronically activated alloreactive T cells increase both glycolysis and mitochondrial OXPHOS through FAO in contrast to proliferating bone marrow cells that are predominantly glycolytic [26] . This preferential metabolic difference was used to selectively block FAO via the use of a small molecule BZ423 that inhibits the mitochondrial ATPase and induces apoptosis of alloreactive T cells. This treatment was shown to reduce GVHD severity without affecting bone marrow reconstitution [26] . This suggests that Teff cells rely upon both glycolysis and mitochondrial OXPHOS to achieve optimal activation and functionality, although the extent of reliance upon one process over the other appears to be context dependent [26,27 & ].
Metabolism in regulatory T cells
Tregs are broadly classified into two types of populations; natural Tregs (nTregs) that are derived from the thymus and induced Tregs (iTregs) that differentiate from naïve T cells in the periphery. Emerging evidence suggests that lipid metabolism is the key metabolic pathway in Treg development and differentiation [28 & ]. On one hand, nTregs depend upon lipogenesis for optimal expression of CTLA-4 and inducible T-cell costimulator (ICOS) that are required for their suppressive function (Fig. 2c ) [28 & ]. On the other hand, iTregs primarily derive their energy from FAO for their development and suppressive function (Fig. 2c) [24] . As such, etomoxir, a drug that blocks FAO [by inhibiting carnitine palmitoyl-transferase-1 (CPT1a), the first ratelimiting enzyme of this process] prevents iTreg generation [24] . Conversely, addition of exogenous FAs promotes Treg generation during CD4 þ T-cell differentiation, whereas strongly inhibiting Th1, Th2, and Th17 cytokine-producing cells.
In addition, Tregs can metabolize extracellular ATP as a mechanism of immunosuppression [29] . The presence of extracellular ATP serves as an indicator of tissue damage and Tregs rapidly degrade ATP via CD39 and CD73 [two members of the ectonucleoside triphosphate diphosphohydrolase (E-NTPDase)] to adenosine that can subsequently bind to A2AR (a type of adenosine receptor) on activated T cells that inhibit their activation [29, 30] (Fig. 2c) . Moreover, mice deficient in CD39 develop autoimmunity and a wasting syndrome associated with poor suppressive capability of Tregs, a condition that is ameliorated by the adoptive transfer of CD39 þ Tregs [29] . These studies indicate that Tregs depend predominantly upon the lipid metabolism for their development and rely upon ATP metabolism in part to mediate their immunosuppressive function [24] .
Metabolism in T memory cells
Metabolism of long-lived memory T cells displays a critical overlapping feature with Treg cells and M2 macrophages as they depend upon FAO to meet their metabolic demands. This is facilitated by IL-15 that promotes mitochondrial biogenesis and expression of CPT1a that is required for FAO [31] . However, unlike iTreg cells that utilize exogenous FAs to fuel FAO, CD8 þ memory T cells use extracellular glucose to synthesize lipids that are further hydrolyzed to generate free FA by lysosomal acid lipase (LAL) to fuel FAO (Fig. 2d ) [32] . Of note, these metabolic features are not invariant, as upon reactivation, human memory T cells have been shown to undergo an immediate-early glycolytic switch for their rapid effector function [33] . This suggests that alloreactive CD8 þ memory T cells could share some overlapping metabolic features with their Teff counterparts and can be targeted in a similar fashion to inhibit their reactivation during tolerance induction.
KEY SENSORS OF METABOLISM
Metabolic and immune signals converge upon the PI3K-phosphoinositide-dependent kinase-1 (PDK1) -protein kinase B (Akt or PKB) signaling pathway, initiating a downstream signaling cascade essential for metabolic reprogramming (Fig. 1) [34] . One of the major downstream targets is mTOR that couples nutrient-energy sensing to protein translation and cell growth that is crucial for maintaining energy homeostasis [35 & ]. It consists of two complexes, mTORC1 and mTORC2, both of which activate a common set of transcription factors. Among the most important of these are hypoxia inducible factor (HIF1a) and c-myc, which together promote the expression of enzymes required for metabolism in immune cells that affect their fate and function [9, 25, 36] . In innate immune cells, mTOR signaling modulates their function between proinflammatory and anti-inflammatory cytokine production such as IL-12 and IL-10 [37, 38] . In CD4 þ T cells, mTORC1 signaling is specifically crucial for Th1 and Th17 differentiation, whereas mTORC2 is vital for Th2 differentiation [39] .
The mTOR signaling pathway is negatively regulated by liver kinase B1 (LKB1) and its downstream target AMP-activated protein kinase (AMPK), two master nutrient sensors, that sense cellular stress (e.g., limiting ATP levels) and promote FAO in CD8 T-cell memory and Treg cells (Fig. 1) [24, 40] . In addition, the phosphatase and tensin homolog (PTEN), an upstream negative regulator of the PI3K-Akt pathway can also inhibit mTOR signaling [41, 42] . AMPK inhibits mTOR signaling via activation of tuberous sclerosis complexes (TSC1/ TSC2). Enhancing mTOR activity via TSC1 deletion in T cells augments Th1 and Th17 differentiation while impairing iTreg suppressive function [43] . These findings parallel with the studies involving chronic hyperactivation of mTOR occurring in circumstances of obesity and overnutrition that can block Treg proliferation and potentially impair their function [3, 44] . Further, absence of TSC1/TSC2 can also impair dendritic cell differentiation and function because of hyperactivation of metabolic pathways such as glycolysis, mitochondrial respiration, and lipid biosynthesis [45] .
Although inhibition of mTOR activity appears to be required for optimal Treg generation and proliferation, recent studies indicate that mTORC1 signaling is actually necessary for optimal Treg suppressive function, as complete absence of mTORC1 signaling impairs the lipid biosynthetic pathway required for their function and migration [28 & ,46] . These recent discoveries indicate that mTOR signaling is dynamic and oscillatory in nature, especially in Tregs, and hence a targeted approach is required to fully exploit the potential of metabolic immunosuppressive treatments for transplantation.
MODULATION OF IMMUNE CELL METABOLISM IN TRANSPLANTATION
Although the idea of mTOR inhibition to inhibit Teff cell function and enhance Tregs looks promising and has yielded encouraging results in rodent transplant models, attempts to translate this into humans has proven difficult. Some of the challenges include recent findings indicating that rapamycin selectively targets mTORC1 without affecting mTORC2 signaling [46] . On one hand, this can induce Akt activation (by phosphorylation at serine 473) by mTORC2 signaling, an event that can destabilize Tregs by inhibiting Forkhead box protein O (FOXO) transcription factors that are required for Treg development and function, and also skew the immune response toward a Th2 phenotype (Fig. 1 ) [39, 47] . On the other hand, prolonged mTORC1 inhibition could block Treg generation and function by blockade of lipogenesis [3, 46] . Furthermore, inhibition of mTOR signaling with rapamycin or metformin (that activates AMPK) after the peak of Teff cell immune response (Fig. 1 ) can promote CD8 memory T cell responses by enhancing FAO and thus can be detrimental for establishing tolerance [40, 48] . Thus, given the complex nature of mTOR signaling, identifying the proper timing and dosage are critical parameters toward effectively using mTOR inhibitors for metabolic alteration in immune cells in a transplant setting.
Despite these challenges, novel strategies to incorporate mTOR and metabolic inhibitors to already existing regimens are being proposed [49 && ]. In line with this, here we suggest conceptual approaches for metabolic interventions in this proposed model (Fig. 3) . Firstly, the addition of IDO/ Arg-1 activators such as CTLA4-Ig that are already known to cause apoptosis of alloreactive T cells via costimulatory blocking mechanisms may have an augmented tolerogenic effects in the early and late phases by inducing tolerogenic dendritic cells and enhancing Tregs. Secondly, the addition of mitochondrial ATPase inhibitors during the induction phase could further augment apoptosis of activated alloreactive T cells along with costimulation blockade regimens. This could be accompanied by the acute inhibition of mTOR (although it is high in alloreactive T cells and low in Treg) via PI3K-mTOR inhibitors that could presumably promote Treg signature genes including (Forkhead box P3) Foxp3 and lipid metabolism in Tregs, whereas inhibiting the activation of alloreactive T cells, thereby tipping the balance towards more Tregs and tolerogenic dendritic cells to achieve tolerance. Addition of glycolytic inhibitors such as ERRa inhibitors or 2 deoxy-glucose (2DG) could also recapitulate the downstream effects of rapamycin [21,49 && ]. However, like rapamycin and metformin, this should be approached with caution as blockade of glycolysis by 2DG can also promote CD8 memory responses that could be detrimental for allograft survival [50] .
Finally, recent studies have shown that altering the nutritional status of a host can also affect the fate and function of Tregs via the adipocytokine leptin-mTOR signaling pathway [51] . Calorie restriction can mimic the effects of rapamycin, by reducing the levels of leptin, and subsequently mTOR activity thereby promoting Tregs while dampening Th1 and Th17 responses [3] . However, calorie restriction is known to activates sirtuins (Sirts), a family of metabolic sensors which are NAD þ (nicotinamide adenine dinucleotide [oxidized]) dependent deacetylases that can deacetylate Foxp3 and target it to proteosomal degradation [36, 52] . In particular, Sirt1 deletion or inhibition in Tregs promotes Foxp3 expression and increases Treg function and prolongs allograft survival [53] .
CONCLUSION
Although current long-term immunosuppressive regimens have improved the survival of allografts significantly, patients still face the danger of graft rejection and complications associated with toxicities of immunosuppressive drugs such as cardiovascular disease, opportunistic infections, and malignancy [29] . Furthermore, a treatment regimen of antibody therapy, steroids, and calcineurin inhibitors globally inhibits both Teff and Treg cell populations [49 && ]. The bioenergetic differences exhibited by immune cells at different stages of tolerance induction therefore serves as promising avenue that can be specifically exploited via the use of mTOR or metabolic inhibitors in combination with dietary therapy to achieve better immune-regulation and functional tolerance to allografts.
